ONCOSCAN ANALYSIS IN RECURRENT GLIOBLASTOMA

Glioblastoma multiforme (GBM) is characterized by unprecedented aggressivity represented by median survival of 12.6 months and very short-time survival with more than 90% 5-year mortality. Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identifi cation of possible predictive and prognostic markers. However new biomarkers in primary and recurrent glioblastoma are desperately required. Used Onco Scan chip technology enables acquisition of genome-wide copy number and loss-of-heterozygosity profiles from FFPE solid tumor samples. OncoScan technology avoids the traditional single locus, low-resolution bottleneck of FISH and PCR. This method was used in comparative analysis of primary and recurrent form of glioblastoma multiforme which supplements and extent our previous work based on cytogenetic characterization of this disease. Although new technologies and of molecularly-cytogenetic analysis progress is each year, the deeper understanding of glioblastoma multiforme is still challenging. This study may provide further insight in comparison of molecular basis in primary and recurrent glioblastoma. Obtained data will be introduced and discussed in poster.

Supported by NT 13581; TE02000058; LF_2014_019; CZ.1.05/ 2.1.00/ 01.0030.